Shares of Novavax Inc. NVAX,
up 2.8% in pre-market trading on Thursday, after the biotech company said it had signed a development and supply agreement with SK Group’s SK Group subsidiary SK Bioscience National for antigenic composition of vaccine candidate COVID-19 of Novavax, NVX-CoV2373. The companies also signed a letter of intent with the Korean Ministry of Health and Welfare to supply NVX-CoV2373 in Korea, as well as the global market. Under the terms of the agreement, SK Bioscience will fabricate the vaccine antigen component during a pandemic. Phase 1
increased 3.3% and the S&P 500 SPX,
has raised 19.9%.